If you or someone you know is in crisis, confidential support is available 24/7 by calling or texting 988 (Suicide & Crisis Lifeline) or texting TALK to 741741 (Crisis Text Line).
Ketamine can quiet suicidal thoughts within hours — sometimes faster than any other tool in psychiatry. That speed has been documented in study after study over the past decade. But the relief tends to fade within a week, leaving clinicians and the people they serve in a painful bind: rapid help that doesn’t last.
A new clinical trial from Stanford Medicine, published May 18, 2026, in the American Journal of Psychiatry, offers the first evidence that a second medication — low-dose buprenorphine — can extend those antisuicidal effects for at least four weeks after a single intravenous (IV) ketamine infusion. The same week, a separate meta-analysis in JAMA Psychiatry reinforced the broader evidence base, confirming across 26 randomized trials and 1,166 participants that IV ketamine meaningfully reduces suicidal and depressive symptoms in the acute phase.
Together, these two publications mark a significant moment: one study deepens what we already know about ketamine’s speed, and the other points toward a practical strategy for sustaining those gains.
Here’s what the research found, what it means for people living with suicidal ideation, and where honest questions remain.
What the Stanford Trial Found
Researchers led by Alan F. Schatzberg, MD, and Jason M. Tucciarone, MD, PhD, enrolled 50 adults with major depressive disorder (MDD) and clinically significant suicidal ideation. Each participant received a single open-label IV ketamine infusion (0.5 mg/kg over 40 minutes). Two days later, they were randomly assigned — in a double-blind design — to receive either low-dose sublingual buprenorphine (0.2 to 0.8 mg/day) or a matched placebo for four weeks. Forty-five participants completed at least one week of follow-on treatment and were included in the primary analysis.
The results, reported by the American Psychiatric Association:
- 76% reduction in suicidal ideation scores in the ketamine-plus-buprenorphine group at week four
- 43% reduction in the ketamine-plus-placebo group at the same time point
- A statistically significant difference between the two groups over time (time-by-treatment interaction, P<0.001)
In quantitative terms, the buprenorphine group’s mean Score for Suicide Ideation (SSI) dropped by 11.6 points compared to 6.3 points in the placebo group (Glass delta 0.76, 95% CI 0.11–1.39).
When participants stopped taking buprenorphine at week four, their suicidal ideation scores rose slightly but still remained below 6 — the threshold for clinically significant suicidal ideation — even at the six-week mark. Withdrawal symptoms were minimal.
“These patients — some of whom have suffered chronically with the idea of dying, of self-harm — within a day get some relief and can build on that relief over a four-week period,” Schatzberg said.
Why Ketamine’s Speed Matters Here
There are currently no FDA-approved treatments specifically for reducing suicidal ideation in people with MDD. Roughly 50,000 people die by suicide in the United States each year. Traditional antidepressants — SSRIs, SNRIs — typically take four to eight weeks to take effect. For someone in acute distress, that wait can be dangerous.
IV ketamine occupies a rare position in this landscape. Administered under medical supervision, a single infusion can begin to reduce suicidal thoughts within hours. The Stanford trial confirms that speed, and adds a second piece: a follow-on treatment that may help those reductions persist well beyond the first week.
Tucciarone highlighted the often-hidden nature of suicidal ideation during the study’s presentation: “Some people are very high-functioning. They’re at work. They have families. They’re holding it down, but yet they harbor these horrible feelings” about suicide.
This observation matters for the broader conversation about ketamine therapy. Suicidal ideation isn’t limited to people in crisis units — it can persist quietly in individuals who appear to be managing daily life.
A Larger Evidence Base Grows Alongside
Published the same week, a systematic review and meta-analysis in JAMA Psychiatry examined 26 randomized controlled trials involving 1,166 patients with major depressive episodes. The analysis found:
- A single IV ketamine infusion significantly reduced suicidal symptoms compared to controls at 24 hours (SMD -0.69) and at one month (SMD -0.70)
- Repeated infusions showed a similar reduction in suicidal symptoms at the end of treatment (SMD -0.72)
- Depressive symptoms improved even earlier — with significant reductions visible at four hours after a single infusion (SMD -1.74)
The authors noted that IV ketamine’s speed of antisuicidal effect could make it a potential option in emergency treatment for people at high risk. However, they also stressed that longer-term outcomes beyond the acute phase remain less well-established.
This meta-analysis matters because it isn’t a single small trial making a claim. It’s a synthesis of 26 studies — one of the highest levels of clinical evidence — that confirms what individual studies have shown: IV ketamine reliably reduces suicidal and depressive symptoms in the short term.
What This Means — and What It Doesn’t
The Stanford trial is a meaningful step forward, but it’s important to be clear about its limits:
- The sample was small. Forty-five participants completed follow-on treatment. Larger trials are needed to confirm the findings and assess safety across a broader population.
- Buprenorphine enhanced the antisuicidal effect but did not significantly reduce depression itself. This hints at a separation between the biology of suicidal ideation and the biology of depression — something the researchers described as “interesting” and worthy of further investigation.
- This was a single-site study. Multi-site replication will be important.
- Neither study claims a cure. The word “cure” doesn’t appear in either paper. What they describe is a measurable, meaningful reduction in suicidal thoughts — an intervention that may help stabilize someone while longer-term treatment takes hold.
As Schatzberg noted: “There is divergence between the antisuicide effect, to some extent, and the antidepressant effect of ketamine. It is somewhat separate — suggesting there’s a different biology and a different pharmacology.”
This finding is scientifically important. It suggests that suicidal ideation may not simply be “severe depression” but may involve distinct neurobiological pathways — pathways that ketamine and buprenorphine may address through different mechanisms.
Why IV Administration and Medical Oversight Matter
Both the Stanford trial and the JAMA Psychiatry meta-analysis focused on intravenous ketamine — not intranasal, oral, or at-home formulations. There’s a reason for that.
IV delivery allows clinicians to control the dose precisely, adjust infusion speed in real time, and monitor vital signs throughout the session. For people experiencing suicidal ideation, this level of medical oversight isn’t just a preference — it’s a safety standard. Ketamine temporarily alters consciousness, can raise blood pressure and heart rate, and may produce dissociation (a feeling of being detached from your body or surroundings). Having trained clinicians present helps manage these effects as they arise.
At Nushama, every ketamine session is medically supervised, with dosing individualized by weight and clinical history. Physicians administer the medicine, and nurses monitor throughout. This mirrors the standard used in the research that produced the outcomes described above.
Preparation and Integration: Where Lasting Change Takes Root
The Stanford researchers observed something that resonated with what we see in clinical practice: rapid pharmacological relief creates a window, not an endpoint.
Ketamine can ease the grip of suicidal thoughts and create space for reflection, connection, and therapeutic work. But that space is most useful when it’s supported by preparation before the session and integration afterward.
Preparation involves working with a clinician or integration coach to set intentions, understand what the experience may be like, and build grounding techniques that can help if difficult emotions emerge during the session.
Integration is the process of making sense of the experience in the days and weeks that follow — translating insights, shifts in perspective, or emotional openings into lasting changes in daily life. It might involve therapy sessions, journaling, community groups, or conversations with a care team.
The Stanford study’s finding that suicidal ideation scores stayed below the clinical threshold even after buprenorphine was stopped suggests that something stabilizing happened during the treatment window. While the study attributes this to the pharmacological effects of the drug sequence, the broader clinical question is: what happens when you combine pharmacological relief with structured therapeutic support?
That’s the approach ketamine-assisted therapy takes — not relying on the medicine alone, but using it as a catalyst within a larger framework of care.
Frequently Asked Questions
Can ketamine treat suicidal ideation?
Research consistently shows that IV ketamine can rapidly reduce suicidal thoughts — often within hours of a single infusion. The 2026 JAMA Psychiatry meta-analysis of 26 randomized trials confirmed significant reductions in suicidal symptoms at 24 hours and at one month. However, ketamine is not FDA-approved specifically for suicidal ideation, and it works best as part of a broader treatment plan that includes therapeutic support and medical oversight.
What did the Stanford ketamine study find?
The Stanford trial, published in May 2026, found that adding low-dose buprenorphine after a single IV ketamine infusion extended the reduction in suicidal thoughts for at least four weeks — significantly longer than ketamine alone. The buprenorphine group saw a 76% reduction in suicidal ideation scores, compared to 43% in the placebo group.
How long do ketamine’s antisuicidal effects normally last?
Without additional treatment, ketamine’s antisuicidal effects typically begin to fade within about a week. The Stanford study explored a pharmacological approach — buprenorphine — to extend that window. Preparation and integration support may also help sustain gains from treatment over time.
Is IV ketamine different from at-home ketamine for suicidal ideation?
The research on ketamine and suicidal ideation has primarily used IV (intravenous) ketamine in medically supervised settings. IV delivery allows precise dosing and real-time monitoring — which is particularly important for people experiencing suicidal thoughts, who may need closer clinical oversight. At-home ketamine formulations have not been studied in the same way for this population.
What is buprenorphine, and is it available now?
Buprenorphine is a medication currently used to treat pain and opioid use disorder. It acts on opioid receptors in the brain. In the Stanford study, a low dose (0.2 to 0.8 mg/day, taken under the tongue) was given after ketamine to help sustain antisuicidal effects. Both ketamine and buprenorphine are available for clinical use, though the specific treatment sequence studied has not yet received FDA approval.
Research in ketamine and suicidal ideation is evolving. If you’d like to learn whether ketamine-assisted therapy may be a fit for your situation, our care team is here to help.
If you or someone you know is experiencing a mental health crisis, please contact the 988 Suicide & Crisis Lifeline (call or text 988), the Crisis Text Line (text TALK to 741741), or call 911.
